|Application ||WB, IHC|
|Calculated MW||82536 Da|
|Other Names||Platelet endothelial cell adhesion molecule, PECAM-1, EndoCAM, GPIIA', PECA1, CD31, PECAM1|
|Target/Specificity||A synthetic peptide corresponding to residues on human CD31/PECAM-1 was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CD31/PECAM-1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Induces susceptibility to atherosclerosis (By similarity). Cell adhesion molecule which is required for leukocyte transendothelial migration (TEM) under most inflammatory conditions. Tyr-690 plays a critical role in TEM and is required for efficient trafficking of PECAM1 to and from the lateral border recycling compartment (LBRC) and is also essential for the LBRC membrane to be targeted around migrating leukocytes. Prevents phagocyte ingestion of closely apposed viable cells by transmitting 'detachment' signals, and changes function on apoptosis, promoting tethering of dying cells to phagocytes (the encounter of a viable cell with a phagocyte via the homophilic interaction of PECAM1 on both cell surfaces leads to the viable cell's active repulsion from the phagocyte. During apoptosis, the inside-out signaling of PECAM1 is somehow disabled so that the apoptotic cell does not actively reject the phagocyte anymore. The lack of this repulsion signal together with the interaction of the eat-me signals and their respective receptors causes the attachment of the apoptotic cell to the phagocyte, thus triggering the process of engulfment). Isoform Delta15 is unable to protect against apoptosis. Modulates BDKRB2 activation. Regulates bradykinin- and hyperosmotic shock-induced ERK1/2 activation in human umbilical cord vein cells (HUVEC).|
|Cellular Location||Isoform Long: Cell membrane; Single-pass type I membrane protein. Cell membrane; Lipid-anchor. Cell junction. Note=Localizes to the lateral border recycling compartment (LBRC) and recycles from the LBRC to the junction in resting endothelial cells|
|Tissue Location||Expressed on platelets and leukocytes and is primarily concentrated at the borders between endothelial cells Isoform Long predominates in all tissues examined. Isoform Delta12 is detected only in trachea. Isoform Delta14-15 is only detected in lung. Isoform Delta14 is detected in all tissues examined with the strongest expression in heart. Isoform Delta15 is expressed in brain, testis, ovary, cell surface of platelets, human umbilical vein endothelial cells (HUVECs), Jurkat T-cell leukemia, human erythroleukemia (HEL) and U-937 histiocytic lymphoma cell lines (at protein level).|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Platelet endothelial cell adhesion molecule-1 (CD31/PECAM-1) is a cell-cell adhesion molecule that is expressed on circulating platelets, on leukocytes, and at the intercellular junctions of vascular endothelial cells, where it mediates the interactions of these cells during the process of transendothelial cell migration, thrombosis, wound healing, and angiogenesis (1, 2). CD31/PECAM-1 is an important target glycoprotein in drug-induced immune thrombocytopenia (DITP), a serious complication of drug treatment (3). CD31/PECAM-1 is the physiological ligand for CD38, where expression in a high percentage of malignant cells is a risk factor for patients with B-cell chronic lymphocytic leukemia (B-CLL) (4).
1. Albelda SM, et al. J Cell Biol. 114(5):1059-68, 1991
2. Kirschbaum NE, et al. Blood. 84(12):4028-37, 1994
3. Kroll H, et al. Blood. 96(4):1409-14, 2000
4. Mainou-Fowler T, et al. Int J Oncol. 33(1):169-74, 2008
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.